Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more
Peplin's Positive Phase II AK Trial Results Published in JAAD read more
Positive Results for Peplin's First Phase III AK Trial read more
Peplin Results for the Quarter Ended 31 March 2009 read more
Peplin owns and operates a GMP licensed, commercial-scale manufacturing facility located in Southport, Queensland, Australia for API production of our proprietary, lead compound PEP005 (ingenol mebutate), a well characterized and purified single molecular entity sourced from a rapidly growing plant called Euphorbia peplus. The entire production process involves cultivation, post-harvest processing, GMP extraction, purification and formulation of PEP005 using strict quality standards for use in clinical trials.
Various contractors based in southeast Queensland and internationally support these activities.